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Abstract
Background: Cachexia affects the majority of patients with advanced cancer and is associated with a reduction in treatment
tolerance, response to therapy, and duration of survival. One impediment towards the effective treatment of cachexia is a
validated classification system.
Methods: 41 patients with resectable upper gastrointestinal (GI) or pancreatic cancer underwent characterisation for
cachexia based on weight-loss (WL) and/or low muscularity (LM). Four diagnostic criteria were used .5%WL, .10%WL, LM,
and LM+.2%WL. All patients underwent biopsy of the rectus muscle. Analysis included immunohistochemistry for fibre size
and type, protein and nucleic acid concentration, Western blots for markers of autophagy, SMAD signalling, and
inflammation.
Findings: Compared with non-cachectic cancer patients, patients with LM or LM+.2%WL, mean muscle fibre diameter was
reduced by about 25% (p= 0.02 and p= 0.001 respectively). No significant difference in fibre diameter was observed if
patients had WL alone. Regardless of classification, there was no difference in fibre number or proportion of fibre type
across all myosin heavy chain isoforms. Mean muscle protein content was reduced and the ratio of RNA/DNA decreased in
patients with either .5%WL or LM+.2%WL. Compared with non-cachectic patients, SMAD3 protein levels were increased
in patients with .5%WL (p = 0.022) and with .10%WL, beclin (p = 0.05) and ATG5 (p = 0.01) protein levels were increased.
There were no differences in phospho-NFkB or phospho-STAT3 levels across any of the groups.
Conclusion: Muscle fibre size, biochemical composition and pathway phenotype can vary according to whether the
diagnostic criteria for cachexia are based on weight loss alone, a measure of low muscularity alone or a combination of the
two. For intervention trials where the primary end-point is a change in muscle mass or function, use of combined diagnostic
criteria may allow identification of a more homogeneous patient cohort, reduce the sample size required and enhance the
time scale within which trials can be conducted.
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Introduction
Cancer cachexia has been defined recently as a multifactorial
syndrome characterised by an ongoing loss of skeletal muscle mass
(with or without loss of fat mass) that cannot be fully reversed by
conventional nutritional support and leads to progressive func-
tional impairment [1]. Cachexia affects the majority of patients
with advanced cancer and is associated with a reduction in
treatment tolerance, response to therapy, quality of life and
duration of survival. Skeletal muscle loss appears to be the most
significant event in cancer cachexia and is associated with a poor
outcome [1,2]. The international consensus on the classification of
cancer cachexia suggested that diagnostic criteria should take into
account not only that weight loss is a signal event of the cachectic
process but that the initial reserve of the patient should also be
considered (either low BMI or low level of muscularity). Although
the latter concept has some validation in terms of clinical risk [2],
there has been no evaluation of the biological correlates in terms of
changes within skeletal muscle itself.
Human skeletal muscle is composed of muscle fibres that are
classified depending on their speed of contraction and predom-
inant type of energy metabolism. Muscle fibres can be classified as
type I (slow-twitch) and type II (fast-twitch) fibres based on their
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predominant myosin heavy chain (MyHC) isoform content.
Generally, type I and type IIa fibres utilise oxidative phosphor-
ylation, whereas type IIx and IIb fibres harness primarily
anaerobic metabolism to generate ATP. Both the percentage
and structural morphology of the fibre type will determine the
phenotypic capacity and functional performance of any given
muscle. Environmental factors in both health and disease have a
direct impact leading to changes in fibre type/morphology and
consequent functionality; such processes include aging, exercise,
chronic disease, and cachexia [3–7]. The change, preservation or
loss of fibres may influence clinical symptoms and there is some
evidence that all types of MyHC is targeted selectively in cancer
cachexia [8]. Ongoing loss of protein in muscle tissue may lead to
muscle fibre shrinkage and a reduction in cross-sectional area
(CSA). Equally, loss of muscle fibre CSA may lead to loss of
aerobic capacity (VO2 max) in healthy subjects as well as cancer
patients [5,9].
Although systemic inflammation is generally thought to be an
important upstream mediator of cancer cachexia [10], the precise
molecular mechanisms that mediate the changes in protein
synthesis and degradation that ultimately lead to atrophy of
muscle fibres in cancer cachexia in humans are not known. For
each animal model that has been studied, different pathways have
been implicated. From such animal models there is a predominant
impression that increased degradation via activation of the
ubiquitin proteasome pathway (UPP) is important [10]. In
contrast, human data is very limited. Activation of protein
degradation via the UPP has not been a consistent finding [11]
[12]. This has led to suggestions that autophagy may be important
or that pathways that may influence both synthesis and
degradation may be important (e.g. TGF-b/SMAD signalling)
[13].
In the present study we chose to evaluate the relationship
between the different cachexia definitions, systemic inflammation
(serum C-reactive protein) and potential inflammatory signalling
pathways within muscle (phospho-STAT3 and phospho-NFkB).
We also examined for potential associations between the various
cachexia definitions and activation of autophagy pathways or
TGF-b/SMAD signalling.
The aim of this study was to investigate the changes in muscle
fibre biology with regards to morphological structure and
composition, to study alteration in various pathways that may
account for altered fibre size and relate these changes to the
different diagnostic criteria that have been proposed as part of the
recent international consensus on the classification of cancer
cachexia [1].
Materials and Methods
Patient Recruitment, Identification, Consent and Ethics
Patients with resectable disease and suitable for the study were
identified via the upper gastrointestinal cancer multi-disciplinary
team (MDT) meetings at the Royal Infirmary, Edinburgh, UK.
Written consent was given prior to entry into the study. All
procedures were approved by the NHS Lothian local research
ethics committee. The study conformed to the standards set by the
Declaration of Helsinki.
Calculation of Weight Loss
Pre-morbid weight was recalled by the patient and verified
where possible from the medical notes. Although there may be
recall bias, evidence to support the reliability of self-reported
weight and weight history [14,15] is well documented. Individual
weight loss was calculated and expressed as percentage of pre-
morbid body weight lost.
Classification of Cancer Cachexia
I. Weight loss .5% over past 6 months (in absence of simple
starvation) (WL.5%)
II. Weight loss .10% over past 6 months (in absence of
simple starvation) (WL.10%)
III. Stature adjusted skeletal muscle index consistent with low
muscularity (LM) (see ‘CT-image analysis’ for cut-offs)
IV. Stature adjusted skeletal muscle index consistent with low
muscularity and any degree of weight loss .2% (LM + .
2%WL)
Rectus Abdominis Muscle Biopsy and Storage For
Biochemical Analysis
All biopsies were taken at the start of open abdominal surgery
under general anaesthesia. Patients had fasted overnight prior to
surgery. The edge of the rectus abdominis was exposed and a
1 cm3 specimen removed using sharp dissection. The biopsy was
cleaned of gross blood contamination. Obvious fat/fibrous tissue
was removed prior to placement in a cryotube and being snap
frozen in liquid nitrogen and stored at 280uC.
Rectus Abdominis Muscle Sample Preparation for Cryo-
Section
A 0.1–0.5 cm3 section of muscle was cut. Liquid nitrogen was
used to cool isopentane solvent in a tube to a temperature of
,2190uC. The section of muscle was stitched onto a segment of
cork. OCT solution was placed at the junction between the cork
base and the muscle. This was then lowered with the cork
uppermost (i.e. muscle first) into cooled solvent and held for
approximately 5 minutes (until the muscle was frozen). Samples
were then stored at 280uC until use.
CT Image Analysis
CT scans used for the analysis were done solely for routine
cancer care. A transverse CT image from the third lumbar
vertebrae (L3) was assessed for each scan date and tissue volumes
estimated [16]. All CT images were analysed by a single trained
observer. Cross-sectional area for muscle and adipose tissue was
normalized for stature (cm2/m2).
Estimates of whole body stores were generated from the raw
data (cm2) using the regression equations by Mourtzakis et al. [17],
which show a close correlation between muscle and fat areas in
CT images at the third lumbar vertebrae and whole body
compartments of fat-free mass (FFM) and fat mass (FM)
respectively.
Total body fat free mass FFMð Þ kgð Þ
~0:3| skeletal muscle at L3 cm2
  
z6:06 r~0:94ð Þ
Total body fat mass FMð Þ kgð Þ
~0:042| total adipose tissue at L3 cm2
  
z11:2 r~0:88ð Þ
The respective indexes for FFM and FM (kg/m2) were calculated.
Cutoffs for low muscularity were based on a CT-based
sarcopenic obesity study of cancer patients by Prado et al. (i.e.,
Clinical Classification of Cancer Cachexia
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L3 skeletal muscle index: #38.5 cm2/m2 for women and
#52.4 cm2/m2 for men) [18].
CT scans used were routine diagnostic staging CT scans which
were performed within 30 days of a diagnosis of cancer and all
were in treatment naive patients. The median time to biopsy after
the CT scan was 18 days.
Immunohistochemistry
The frozen muscle sections were co-stained for laminin (L9393,
Sigma-Aldrich, Buchs, Switzerland) and myosin heavy chain type I
or IIa to distinguish each fibre type (BA-D5 for type I, SC-71 for
type IIa). The paraffin sections were stained for phospho-STAT3
(D3A7, Cell Signaling Technologies, Danvers, MA, USA) with a
Ventana discovery XT (Roche group, Tucson, USA). Images of
the entire tissue section were acquired using a VS120 slide scanner
(Olympus Corporation, Tokyo, Japan). The distribution of myosin
heavy chain fibre types, the cross section area of the individual
fibres in the section, and the phospho-STAT3 positive nuclei and
staining density were analysed using the proprietary image analysis
platform ASTORIA (Automated Stored Image Analysis) devel-
oped by Novartis/Preclinical Safety.
Tissue Preparation for DNA, RNA and Protein Extractions
Skeletal muscle tissue was minced and ground on dry ice.
Aliquots were weighed using an analytical balance (Mettler
Toledo) and stored at 280uC until use.
DNA and RNA Extraction and Linearity of the Extraction
Method
DNA and RNA from human skeletal muscle tissue was
extracted and purified with the automated Maxwell 16 system
(Promega, Duebendorf, Switzerland). To determine the linearity
of the extraction methods using the Maxwell 16 system, DNA and
RNA was extracted from 4 mg, 6 mg, 8 mg, and 10 mg of muscle,
respectively. Calculating the total DNA and RNA content per wet
weight (which in a linear extraction system should be equal for all
aliquots), allowed us to define the linear range of the Maxwell 16
extraction system. Based on these preliminary studies, aliquots of
4–8 mg human skeletal muscle tissue were used for all subsequent
DNA and RNA extractions. Using more starting material
drastically reduced the total DNA and RNA content per wet
weight (data not shown).
For DNA extraction, the Maxwell 16 LEV Blood DNA Kit
(Promega) was used with a slightly adapted protocol compared
with the manual’s instructions. Briefly, 300 ml of Tail Lysis Buffer
from the kit ReliaPrep gDNA Tissue Miniprep System (Promega)
was added to minced and ground human skeletal muscle tissue in
Precellys 24 lysing kit tubes. Tissue was further homogenized using
the high-throughput homogenizer Precellys 24, for 10 s. After
cooling on ice for 5 minutes, 30 ml of the protein K and 5 ml of the
1-Thiolglycerol solution were added. This mixture was incubated
at 56uC for 2 hrs. Afterwards, the lysate was transferred into well 1
of the LEV Blood DNA cartridge, and diluted with 300 ml
nuclease-free water. For the elution, 50 ml of elution buffer was
added into elution tubes. The Maxwell 16 instrument was started
using the DNA Blood program.
For RNA extraction, the Maxwell 16 LEV simplyRNA Tissue
Kit was used (Promega), following the manual’s instructions.
Briefly, minced and ground human muscle tissue was incubated in
200 ml of chilled 1-Thioglycerol/Homogenization solution and
further homogenized using the Precellys 24 system (see DNA).
Afterwards, the samples were heated at 70uC for 2 min, then the
lysates were allowed to cool down. 200 ml of lysis buffer was added
to the cooled-down homogenate, mixed vigorously, followed by
transfer of the total 400 ml into well 1 of the Maxwell 16 LEV
cartridge. 5 ml of DNAse was added to well 4 of the cartridge and,
50 ml RNAse-free water was added to 0.5 ml Elution Tubes and
the RNA extraction program was started at the Maxwell 16
instrument.
Extracted DNA and RNA were measured spectrometrically
using a Trinean DropSense Instrument (Trinean, Gentbrugge,
Belgium) for quantity and quality.
Protein Extractions
To extract proteins, 300 ml of PhosphoSafe Extraction Reagent
(Millipore) was added to a specific amount (between 8 and 18 mg)
of homogenized human skeletal muscle tissue. To further
homogenize the samples, the Precellys 24 system was used (see
section above). After incubation on ice for 5 min, the lysates were
spun at 8006g for 5 min at 4uC. Supernatants were transferred
into new tubes and spun for another 12 min at 16006g at 4uC.
Supernatants were collected and protein concentrations measured
using the BCA Protein Assay Kit (Pierce) with BSA as a standard.
Afterwards, phosphatase inhibitor cocktail (Roche) was added and
the samples were stored at 280uC until further use.
Western Blots
20 mg of human skeletal muscle protein extracts (see above) in
reducing Laemmli SDS sample buffer were boiled for 5 min at
95uC and then separated by SDS-PAGE on 4–20% gradient gels
(Bio-Rad, Cressier, Switzerland), blotted to Nitrocellulose mem-
branes (Bio-Rad) using the Trans-Blot Turbo Transfer System
(Bio-Rad), blocked for 1 h in 5% non-fat milk in Tris-buffered
saline+0.05% Tween-20, incubated overnight with primary
antibody, rinsed, and incubated for 1 h with peroxidase-conjugat-
ed goat anti-rabbit IgG (1:5000) (Santa Cruz, Heidelberg,
Germany) at room temperature. Blots were developed using
ECL (Roche, Rotkreuz, Switzerland) or SuperSignal West Femto
substrate (Thermo Scientific, Wohlen, Switzerland) and exposed to
Kodak film (Kodak, Rochester, NY, USA).
Rabbit monoclonal antibodies used were: Beclin-1 (clone
D40C5), Atg5 (clone D1G9) , Atg7 (clone D12B11), Atg12 (clone
D88H11), SMAD3 (clone C67H9), phospho-NFkB p65 (Ser536)
(clone 93H1) and a-tubulin (clone 11H10) (all from Cell Signaling
Technologies, Danvers, MA, USA), phospho-SMAD3 (Ser423/
Ser425, clone EP823Y) (Millipore, Billerica, MA, USA). Rabbit
polyclonal antibodies used were: Gelsolin (Cell Signaling Tech-
nologies).
Western blots were analyzed densitometrically using ImageJ
software version 1.45 (NIH, Bethesda, MD, USA; http://rsbweb.
nih.gov/ij). Band intensity of each sample was normalised to that
of a-tubulin.
C - Reactive Protein (CRP)
Serum CRP concentration was measured with an automated
immunoturbidimetric assay by clinical chemistry department,
Royal infirmary Edinburgh, using blood collected from patients at
the time of recruitment and before any therapeutic intervention.
Statistical Analysis
Results are expressed as mean (6 SEM). Comparisons between
groups were performed using unpaired Student’s t tests, whereas
possible relationships were evaluated using Pearson’s correlations.
Results were considered significant if p values were less than 0.05.
The program SPSS (version 20, SPSS, Chicago, IL, USA) was
used for all the statistical tests.
Clinical Classification of Cancer Cachexia
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Results
Patient Demographics
A total of 41 cancer patients with resectable UGI or pancreatic
cancer were recruited. In general, patients were over 65 years of
age, predominantly male and had sustained, on average, 5% loss
of weight compared with pre-illness levels (Table 1). Patients were
grouped based upon the concepts of the International Classifica-
tion Framework [1] according to weight loss or weight loss in
association with low muscularity. The specific phenotypes
considered were weight loss .5% (WL.5%), weight loss .10%
(WL.10%), low muscularity (LM), and LM with weight loss .2%
(LM+.2% WL). Although BMI was reduced in all groups
classified as cachectic, only the LM and LM+.2% WL groups
had a significantly lower fat free mass index (Table 1).
Muscle Fibre Size, Number, and Type
If patients were classified as cachectic by LM or LM +
.2%WL, fibre size was reduced significantly (all types of myosin
heavy chain fibre) when compared with non-cachectic patients
and controls (Figure 1A). The association of cachexia with reduced
fibre size was not observed if patients were classified according to
WL alone. Representative immunohistological sections demon-
strating differences in fibre diameter between a healthy control
and an individual in Group II versus Group IV is shown in
Figure 1B. Immunohistology for type I and IIa resulted in
complementary staining in general, whereas fibre type IIb resulted
in very low staining intensity as reported elsewhere [19]; therefore
quantitative analysis was done only with type I and IIa but not
with type IIb (Table 2). As would be expected from a decrease in
fibre size, there was a trend across all groups for fibre density to
increase in those with cachexia. However, due to large variability,
this was not statistically significant. There was no evidence of
selective fibre atrophy across any of the classification groups
(Table 2).
Protein Content
The results for skeletal muscle protein content are shown in
Figure 2(A). When compared with non-cachectic patients, muscle
protein content was reduced significantly (approximately 13%) in
patients with either .5% WL or LM + .2%WL (Figure 2A and
table 3). However if the LM criteria were applied alone no
difference in the protein content was observed. In addition,
patients with .10% WL showed a 10% reduction in protein
content when compared with non-cachectic patients but this
difference did not reach statistical significance (Figure 2A and
table 3).
RNA, DNA, and RNA/DNA Ratio
The results for skeletal muscle DNA and RNA content are also
shown in Figure 2(B,C, and D) and table 3. RNA content was not
significantly different in cachectic patients when compared with
non-cachectic patients according to any of the diagnostic criteria
(Figure 2B and table 3). In contrast, DNA content was increased
by 50% with .5% WL but decreased by ,40% in patients with
LM (Figure 2C). The ratio of RNA/DNA was decreased
(approximately 30%) in patients with .5% WL and LM +
.2%WL (Figure 2D).
Autophagy Pathways
In patients with .10% WL, Beclin and ATG5 protein levels
were increased significantly in cachectic patients when compared
with non-cachectic patients (Figure 3). ATG7 and 12 levels were
not different in cachectic patients when compared with non
T
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– cachectic patients according to any of the diagnostic criteria
(Table 3).
SMAD Signalling
In patients with .5% WL, SMAD3 protein levels were
significantly increased when compared with non-cachectic patients
(Figure 4). There were no significant differences in phospho-
SMAD3/SMAD3 across any of the groups (Figure 4).
Inflammatory Pathways
Systemic inflammation was estimated using patients’ serum
CRP levels (Table 1). Patients were classified as having systemic
inflammation if their CRP was $10 mg/L. There was no
Figure 1. Fibre type cross sectional area (FCSA) according to different definitions of cachexia. (A) Mean (6 SEM) fibre size for both
MyHC1 and MyHCIIa. A comparison is made between patients with the proposed cachexia definition absent (dark grey) and those with the proposed
cachexia definition present (light grey) for the four definitions set out in Methods (I–IV). (*, P,0.05 and **, P,0.01, by Student’s t test). (B)
Immunohistological sections of muscle for a healthy control, patient with weight loss alone (10.1%) (Group II), and patient with low muscularity and
.2% weight loss (Group IV). Laminin is shown in green, MyHC1 shown in red, and MyHCIIa is shown in blue.
doi:10.1371/journal.pone.0083618.g001
Clinical Classification of Cancer Cachexia
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difference in the proportion of patients with or without systemic
inflammation according to the definition of cachexia. Levels of
phospho-NFkB and phospho-STAT3 were not significantly
different in patients with or without cachexia (using any of the
definitions: table 4) or with or without systemic inflammation
(Figure 5).
Discussion
Fibre Size
The diagnostic criterion for cancer cachexia has long been
based on weight loss alone [1] and can reflect loss in either fat or
lean tissue compartments. Given that the key tissue loss in cancer
cachexia is considered to be skeletal muscle, a recent consensus
process suggested that the diagnostic criteria for cachexia should
also take account of low baseline levels of muscularity [1]. In the
present study, when patients were classified as cachectic or not
according to $5% weight loss there was no significant difference
in whole body muscularity (FFMI) or muscle fibre CSA. In
contrast, when patients were classified according to low muscu-
larity and $2% weight loss, FFMI was decreased and fibre cross
sectional area was also significantly reduced (Figure 1). Such
findings demonstrate that heterogeneity in relation to low
muscularity and fibre atrophy may be reduced according to the
clinical definition of cachexia. This finding may be important
especially when considering inclusion criteria for clinical trials that
aim to test the efficacy of drugs targeted at reversal of muscle
wasting in cancer patients. The reduction in fibre size in all MyHC
isoforms observed in the present study is consistent with previous
animal [20] and human studies of cancer cachexia [4–7]. The
rectus muscle of patients with oesophago-gastric cancer cachexia
has been shown to lose all type MyHC content as well as undergo
a reduction in fibre size [4]. Equally, in pancreatic cancer patients
with cachexia, both type I and type II MyHC protein levels were
decreased by 45% when compared with controls [6].
Fibre Type
In order to study differences in muscle fibre morphology and
composition within the different cachexia categories, we per-
formed immunohistochemical analysis of human muscle samples.
For that, we first established and validated the staining methods
for the myosin heavy chain antibodies specific for the different
fibre types (I, IIa, and IIb). Staining for type I and IIa fibres
resulted in strong specific staining specificity, however only weak
Figure 2. Variations in protein and nucleic acid content according to the different definitions of cancer cachexia. A comparison is
made between patients with the proposed cachexia definition absent (dark grey) and those with the proposed cachexia definition present (light
grey) for the four definitions set out in the methods (I–IV). (A) Mean (6 SEM) wet weight protein content. (B) Mean (6 SEM) RNA content. (C) Mean
(6 SEM) DNA content. (C) Mean (6 SEM) RNA/DNA ratio. (*, P,0.05 by Student’s t test).
doi:10.1371/journal.pone.0083618.g002
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staining was observed against type IIb MyHC, this finding has also
been reported elsewhere [19]. The predominant types of MyHC
fibre in rectus abdominis muscle are I and IIa and only ,8% of
type IIb positive fibres have previously been described [21]. Of the
adult skeletal isoforms, each are expressed to varying degrees in
both mouse and human skeletal muscle. However, although
MyHCIIb is highly expressed at both the messenger RNA
(mRNA) and protein level in murine skeletal muscle, evidence to
date suggests that this isoform is effectively only expressed at the
mRNA level in a very small subset of specialised muscles in the
adult human [22]. As mentioned above, MyHCIIb expression is
typically associated with high forces of contraction combined with
rapid contractile characteristics and it has been suggested that the
contractile characteristics of MyHCIIb may be incompatible with
the biomechanical constraints of larger muscles [23], which may
account for the lack of specificity found in the rectus muscle of our
patient population.
In cachexia there is conflicting evidence as to whether there is
selective loss of fibre type. There was no evidence for selective loss
of fibre type in the present study (Table 2). Evidence from animal
models suggests that Type II fibres are targeted selectively [24],
with relative preservation of type I fibres in fasting [25], exposure
to glucocorticoids [26], sepsis [27] and in the gastrocnemius
muscle of the C26 model of cancer cachexia [28,29]. Models of
cardiac cachexia, however have suggested a trend to selective loss
of type I fibres and an increase in type II fibre [30]. Furthermore,
not all groups have demonstrated Type I and II fibre differences
even in animals. Indeed in a recent study of the C26 cachectic
mouse model, both glycolytic and oxidative fibres of (extensor
digitorum longus) EDL muscle underwent wasting [20], whilst in a
previous study using the same mouse model there was a significant
increase in the amount of MyHCIIb and a significant decrease in
the amount of type 1 MyHC in soleus muscle [31]. It is currently
not entirely clear which type of fibres are affected in human cancer
cachexia, however, in patients with oesophago-gastric cancer
cachexia early loss of all MyHC isoforms has been reported [4].
The activity patterns of a muscle are also key in determining
phenotype. If muscle cells are recruited infrequently they develop
into fast/glycolytic units whereas if they are recruited more often,
they form slow/oxidative units. In the C26 mouse model of cancer
cachexia, there have been reports of switching of myosin isoforms
in the soleus muscle of cachectic mice [31]. In pancreatic cancer
patients with cachexia, no difference in the ratio of fast/slow
myosin isoform was demonstrated compared with controls [6].
Muscle RNA, DNA, and Protein Content
In the present study, when compared with non-cachectic
patients, muscle protein content was reduced significantly
(approximately 13%) if patients were classified as cachectic by
either .5% WL (p= 0.015) or LM + .2%WL (p= 0.035), and by
10% in patients with .10% WL. Protein content expressed in
relation to wet weight of muscle has been shown to decrease
progressively (in excess of 50%) in the gastrocnemius muscle of
mice bearing the MAC-16 tumour [32]. This suggests that not
only is there loss of fibre diameter, but that the quality of the fibre
is altered with loss of either sarcoplasmic or myofibrillar protein.
Such changes in fibre composition may contribute to the reduced
muscle mechanical quality (force per unit cross-sectional area)
observed in human cancer cachexia [33].
A reduction in both RNA content and activity in skeletal muscle
has been attributed to a depression of protein synthesis in mice
bearing the MAC16 tumour [32] . In the present study, RNA
content was unaltered in cachectic patients (classified either with
.5% WL or LM + .2% WL) compared with non-cachectic
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Figure 3. Skeletal muscle Beclin and ATG5 protein levels in patients with or without .10% weight loss (Group II). Western blot
analysis with indicated antibodies, a-tubulin was used as a loading control. Graph shows the mean (6 SEM) protein level represented in arbitrary
units (A.U). (*, P,0.05 and **, P,0.01, by Student’s t test).
doi:10.1371/journal.pone.0083618.g003
Figure 4. Total SMAD3, phospho-SMAD3 and ratio of phospho-SMAD3/SMAD3 in patients with or without .5% WL (Group I)
levels. Western blot analysis with indicated antibodies, a-tubulin was used as a loading control. Graph shows the mean (6 SEM) protein level
represented in arbitrary units (A.U). (*, P,0.05 by Student’s t test).
doi:10.1371/journal.pone.0083618.g004
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patients. A reduction in the RNA content in the muscle of mice
bearing the Ehrlich ascites tumour has also been reported, but this
occurred later than the observed depression in the rate of protein
synthesis [34]. Whether muscle protein synthesis is depressed in
human cancer cachexia remains to be resolved [10].
In a murine model of cancer cachexia DNA content of the
gastrocnemius muscle has been shown to remain relatively
constant, despite the finding of a decrease in protein and RNA
content [32]. The current study demonstrated DNA content was
increased by .50% with .5% WL but decreased by 40% in
patients with LM (Figure 2C). Because mature myofibre nuclei are
thought to be mitotically inactive, increased DNA content in
skeletal muscle cells suggests activation of satellite cells [35] or
infiltration by other cell types such as inflammatory cells or
adipocytes. In the LM group, the decrease in DNA may be due to
pre-existing age-related sarcopenia or other causes of muscle
atrophy (e.g. immobilisation) and may relate to muscle specific
apoptosis and reduction in cell number in keeping with a reduction
in muscle mass on CT scanning. The diametrically opposite
changes in muscle DNA content dependent on whether patients
are classified according to weight-loss or low muscularity again
underpin the potential diverse mechanisms whereby older cancer
patients may develop a low level of muscularity.
The issue of whether nuclear domain size is reduced in cancer
cachexia remains to be resolved. In particular, whether apoptosis
in skeletal muscle is increased in cancer cachexia and the degree to
which DNA content is maintained or not via a compensatory
increase in myonuclear number (possibly via satellite cell nuclei
incorporation) is not known. Features of cachexia such as
hypogonadism (resulting in low testosterone) or systemic inflam-
mation (associated with high IL-6) could influence such regener-
ative capacity. In the current study RNA/DNA was altered in the
cachectic patients (independent of definition) compared with the
non- cachectic patients. This may be due to the interplay of the
mechanisms described above.
Mechanisms
Skeletal muscle atrophy may occur as a result of decreased
synthesis, increased degradation or both [36]. In mice bearing the
MAC-16 adenocarcinoma, muscle loss is due to the combination
of reduced synthesis and increased degradation [37]. Similarly
Samuels et al demonstrated reduced protein synthesis and
increased degradation in skeletal muscle co-incident with the
onset of cachexia in mice implanted with the C26 murine model
[38].
Degradation Pathways. The majority of signalling pathways
contributing to muscle atrophy in pre-clinical models are mediated
through activation of the ubiquitin-proteasome proteolytic path-
way (UPP) [39]. The muscle-specific E3 ubiquitin ligases, MuRF-1
and MAFbx/atrogin-1 are up regulated in animal models of acute
Figure 5. Inflammatory pathways in patients with (CRP .10 mg/L) and without (CRP #10 mg/L) systemic inflammation. (A) Western
blot analysis in the presence or absence of systemic inflammation with indicated antibodies, a-tubulin was used as a loading control. (B) Graph shows
the mean (6 SEM) protein level of phospho-NF-kB, represented in arbitrary units (A.U). (C) Representative immunohistochemistry and nuclei count of
phospho-STAT3 (area shown is representative of field) of a patient with or without systemic inflammation. (D) Graph shows the staining density of
phospho-STAT3 nuclei (A.U.) (6 SEM) in the presence or absence of systemic inflammation.
doi:10.1371/journal.pone.0083618.g005
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atrophy [40,41], and MuRF1 selectively targets the myofibrillar
protein myosin heavy chain resulting in muscle wasting [8].
However, the role of the E3 ligases in human cachexia is less well
defined. In the current study we chose not to measure directly
these pathways as results from our previous investigation on a
similar cohort of patients found no up regulation using a
transcriptomics approach [42], this has also been validated
recently in a separate cohort of patients with gastric cancer [43].
In the present study autophagy proteins (ATG) 5, 7, 12, and beclin
1 were studied. These proteins are necessary for autophagy due to
their role in autophagosome elongation [44]. When patients were
classified according to.10%WL, Beclin and ATG5 protein levels
were significantly increased in cachectic patients when compared
with non-cachectic patients. In a previous study in a similar cohort
of patients, the autophagy related genes GABRAPL1 and BNIP3
were increased in rectus muscle biopsies from cachectic versus
non-cachectic patients [42]. In normal muscle, low-protein diets
up-regulate autophagy that leads to the loss of muscle mass at least
partially through lysosomal degradation [45]. Intriguingly, under
other circumstances decreased autophagy can also lead to muscle
atrophy.
Systemic Inflammation. Systemic inflammation is thought
to be a major mediator of cancer cachexia [10]. However, the
relationship between inflammation in the systemic compartment
versus muscle and the relationship of either to muscle loss in
humans is not clear. In the systemic compartment, Il-6 is thought
to be a major mediator and may signal within target organs via
STAT-3. Alternatively, both IL-1 and TNF alpha may signal via
NF-kB. NF-kB regulation of muscle atrophy is predominantly
executed by promoting proteasome-mediated degradation [46].
Activation of NF-kB has been detected in both physiological and
pathological atrophic conditions such as denervation, unloading,
aging, cancer, sepsis, diabetes, and such atrophy can be reversed
by pharmacologic or genetic NF-kB inhibition [47]. In the present
study although there was evidence for systemic inflammation in a
proportion of patients, no significant difference was found in the
levels of phospho-NFkB or phospho-STAT3 across any of the
definitions of cachexia or in those with or without evidence of
systemic inflammation. It is possible that inflammatory mediators
have their main effects on muscle atrophy via central mechanisms
mediated via the CNS [48].
SMAD3. It has been suggested that binding of myostatin to
the ActRIIB receptor results in the phosphorylation of two serine
residues of SMAD2 or SMAD3. This leads to the assembly of
SMAD2/3 with SMAD4 to the heterodimer that is able to
translocate to the nucleus and activate transcription of target genes
[49]. One of the known downstream targets of SMAD signalling is
MyoD, a transcriptional factor that is involved in skeletal muscle
development and takes part in the repair of damaged skeletal
muscle [50]. Moreover, SMAD signalling targets other genes such
as myf5 and myogenin, known to be important for myogenesis
[51]. Myostatin is upregulated in cachexia and in states of muscle
paralysis [52]. Myostatin/ActRIIB activates SMAD2/3 signalling
and importantly SMAD2/3 inhibition completely desensitises
ActRIIB-induced muscle atrophy [13]. Inhibition of myostatin by
a dominant negative ActRIIB promotes muscle hypertrophy
independent of muscle satellite cell recruitment consistent with a
direct signalling effect on muscle catabolism [13]. When patients
were classified as cachectic according to .5% WL, SMAD3
protein levels were significantly increased in cachectic patients
when compared with non-cachectic patients. Equally there was a
similar (but not significant) increase in phospho-SMAD3 associ-
ated with.5% weight loss. It is not known whether such increasedT
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protein levels indicate increased pathway activity independent of
any alteration in the ratio of phospho-SMAD3/SMAD3.
Limitations of Study
It is important to appreciate that the majority of patients in the
present series will have had some degree of age-related sarcopenia,
that this will necessarily co-exist with any cancer specific loss of
skeletal muscle mass and that the diagnostic criteria used in the
present study will not necessarily separate one from the other. The
current study was not longitudinal and it was therefore not possible
to document active muscle loss. It is also important to recognise
that when patients were divided into different diagnostic categories
the sample size in individual categories may have limited the
ability to detect a statistical difference or not. This was an
exploratory study and provides the basis for a larger study with
adequate statistical power for definitive analysis.
Conclusions
In the present study, when the diagnostic criteria for cachexia
included both a measure of low muscularity and weight loss,
muscle fibre size, protein content and RNA/DNA content were all
reduced. Such consistent findings were not observed when
cachexia was diagnosed based on weight-loss or low muscularity
alone. Whereas fibre type is not targeted selectively, muscle fibre
size, biochemical composition and pathway phenotype can vary
according to whether the criteria for cachexia include both a
measure of low muscularity and weight loss. Such findings suggest
that current diagnostic criteria identify groups of patients with
different skeletal muscle phenotypes. Identification of a more
homogeneous patient cohort for musculo-centric intervention
trials may require use of combined criteria.
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